Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vivani Medical, Inc. (EYES)
|
Add to portfolio |
|
|
|
| Price: |
$1.19
| | Metrics |
| OS: |
50.8
|
M
| |
|
|
| Market cap: |
$60.5
|
M
| |
|
|
|
Net cash:
|
$32.5
|
M
| |
$0.64
|
per share
|
|
EV:
|
$28
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.0 | 3.4 | 6.9 | 8.0 | 4.0 | 9.0 | 1.4 |
| Revenue growth | | -100.0% | -51.0% | -13.4% | 99.8% | -55.5% | 521.1% | -7.9% |
| Cost of goods sold | -0.1 | -0.5 | 2.2 | 4.9 | 5.1 | 10.1 | 5.4 | 3.6 |
| Gross profit | 0.1 | 0.5 | 1.2 | 2.0 | 2.8 | -6.1 | 3.6 | -2.2 |
| Gross margin | | | 36.3% | 29.1% | 35.7% | -152.8% | 39.8% | -150.0% |
| Sales and marketing | | 0.7 | 6.1 | 11.3 | 9.6 | 9.0 | 8.9 | 6.8 |
| Research and development | 2.4 | 4.8 | 13.1 | 10.0 | 7.9 | 5.3 | 3.0 | 5.2 |
| General and administrative | 6.3 | 5.9 | 9.2 | 10.7 | 10.9 | 10.1 | 8.2 | 6.6 |
| EBIT | -8.9 | -12.7 | -30.6 | -34.6 | -28.6 | -33.2 | -20.0 | -21.2 |
| EBIT margin | | | -905.5% | -502.1% | -359.2% | -833.4% | -224.0% | -1473.5% |
| Pre-tax income | -8.9 | -14.9 | -33.6 | -35.1 | -28.5 | -33.2 | -20.0 | -35.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -8.9 | -14.9 | -33.6 | -35.1 | -28.5 | -33.2 | -20.0 | -35.2 |
| Net margin | | | -994.1% | -508.9% | -358.1% | -832.6% | -223.7% | -2442.8% |
| |
| Diluted EPS | ($0.27) | ($0.72) | ($2.28) | ($4.23) | ($0.53) | ($0.84) | ($0.56) | ($1.41) |
| Shares outstanding (diluted) | 32.8 | 20.6 | 14.7 | 8.3 | 54.2 | 39.6 | 35.6 | 25.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|